Currax Pharmaceuticals today announced the FDA approved a second manufacturing site for its Contrave medication. The approval of the second site enhances the production capacity for the company’s oral weight loss medication, also marketed as Mysimba in Europe. Currax said it is investing in manufacturing and advancing clinical research. “At Currax, we are steadfast in…